In the eastern reaches of Congo, where the rainforest meets the crowded edges of human settlement, an old and merciless virus has found fertile ground once again. The Bundibugyo strain of Ebola, for which no approved vaccine yet exists, has now claimed more than a thousand lives, and the people who stand between the sick and the grave are themselves refusing to work without pay. It is a reminder that epidemics are never only biological events; they are tests of whether the structures of care, trust and wages can hold when they are most needed. Researchers have begun a slow search for treatment
Congo Ebola Deaths Pass 1,000 as Health Worker Strikes Threaten Containment Efforts
Over 1,000 people have died and thousands have been infected, while health workers risk their lives unpaid and attacks on health centers continue.
80 percent of new cases come from unknown chains of transmission
Mark
Why do the strikes matter so much to the outbreak itself?
Mimi
Because the strikers are the tracing and burial machinery. Case investigators, drivers, gravediggers, epidemiologists. If they stop, so does finding contacts and safely burying the dead.
Mark
And they went back to work at one center?
Mimi
Conditionally. They agreed to resume if the government pays within 72 hours. Then a new strike started at Bunia General Hospital.
Luke
Worth noting that officials only say they're in talks. Nothing in the reporting says payment has been made or when it will be.
Mark
The numbers seem to vary. What do we actually know?
Luke
Over 2,000 cases and over 750 deaths are described as confirmed. The figure of over 1,000 deaths is in the headline, but the reporting doesn't explain how it differs from the confirmed count.
Mimi
The bigger worry is that 80 percent of new cases come from unknown transmission chains, according to the WHO.
Mark
So nobody knows how far it has spread?
Luke
Right. Suspected cases in two more provinces, including Kisangani, are suspected, not confirmed. And the origin is still unknown.
Mark
What about the treatment trial?
Mimi
Remdesivir and MBP134 are being tested, but only at one center in Ituri so far.
Luke
And the lab hints for remdesivir are just that, hints. The WHO says answers could take months and up to 1,000 participants.
El Pulso
- Health workers in Ituri have shut a treatment center and blocked access, demanding payment within 72 hours before they will return.
- A second walkout has barricaded the entrance to Bunia General Hospital, threatening to spread through already fragile facilities.
- Four in five new infections arise from chains of transmission no one can trace, leaving responders chasing a fire they cannot see.
- Suspected cases in two more provinces, including near the large city of Kisangani, raise the stakes of every stalled day.
- A remdesivir and MBP134 trial has started, but it may need up to 1,000 participants and months before any answer emerges.
In the eastern reaches of Congo, where the rainforest meets the crowded edges of human settlement, an old and merciless virus has found fertile ground once again. The Bundibugyo strain of Ebola, for which no approved vaccine yet exists, has now claimed more than a thousand lives, and the people who stand between the sick and the grave are themselves refusing to work without pay. It is a reminder that epidemics are never only biological events; they are tests of whether the structures of care, trust and wages can hold when they are most needed. Researchers have begun a slow search for treatments, but the answer will take months, and in the meantime the fight depends on whether those who carry it out can be kept at their posts.
On Monday, staff at an Ebola treatment center in Ituri province, the heart of Congo's outbreak, shut the doors and blocked access. They were epidemiologists, case investigators, drivers and gravediggers, the people who find the sick, carry them to care and bury the dead. They had worked through weeks of dangerous crisis duty with little or no pay from the government, and they agreed to return only if they were paid within 72 hours.
On Wednesday a second strike began at Bunia General Hospital, where workers barricaded the entrance. Officials say they are negotiating. Every walkout at an already underequipped facility weakens containment in a region strained by rebel threats and by misinformation that insists the virus is not real.
The outbreak is now the fastest-growing Ebola outbreak on record. More than 2,000 cases have been recorded and the reported death toll has passed 1,000. The World Health Organization says 80 percent of new cases come from transmission chains that cannot be traced, and the origin of the outbreak remains unknown. Suspected cases have appeared in two more provinces, one of them home to Kisangani.
Attacks on health centers, suspicion of outsiders and restrictions on traditional funerals have all deepened the difficulty. Part of the outbreak lies in Goma, a city seized by rebels more than a year ago.
As the strikes unfold, researchers have started testing treatments. Remdesivir and Mapp's experimental MBP134 are being compared against standard care at one center in Ituri. Results could take months. For now, the people watching closest will be looking at three things: whether the strikers are paid, whether the Bunia walkout spreads, and whether the suspected cases are confirmed.
On Monday, the staff of an Ebola treatment center in Ituri province, the epicenter of Congo's outbreak, shut the doors and blocked access. The people walking out were not a single type of worker: epidemiologists, case investigators, drivers and gravediggers, all of them part of the machinery that finds the sick, moves them and buries the dead. They had spent weeks on risky crisis work and received little or no pay from the Congolese government. They agreed to go back on one condition: payment within 72 hours.
On Wednesday, a second strike began, this time at Bunia General Hospital, where workers barricaded the entrance. Congolese officials say they are in talks to find a solution. A strike that spreads to more overstretched, underequipped facilities would be another serious blow to containment, in a region that already has bare-bones infrastructure, rebel threats and misinformation insisting the virus is not real.
The outbreak is now the fastest-growing Ebola outbreak in history. More than 2,000 cases have been confirmed, including more than 750 deaths, though the headline toll of deaths has passed 1,000. Cases are now suspected in two more provinces, one of them home to Kisangani, one of Congo's largest cities. The World Health Organization said Tuesday that 80 percent of new cases are coming from unknown chains of transmission, meaning responders cannot trace where those people caught the virus. The origin of the outbreak is still unknown.
The cause is the Bundibugyo virus, a rare type of Ebola with no approved vaccine. Ebola can pass to people from wild animals and then spreads among humans through contact with bodily fluids such as vomit, blood or semen, and through contaminated surfaces and materials like bedding and clothing. Symptoms include fever, vomiting, diarrhea, muscle pain and, at times, internal and external bleeding. The disease is severe and often fatal, and outbreaks tend to start in remote villages in Central Africa near rainforests.
The setting makes the work harder. Associated Press journalists have seen the aftermath of attacks on health centers by a wary, highly mobile population long traumatized by armed groups. Outsiders are often viewed with suspicion, and community outreach teams have kept spreading prevention messages despite abuse and accusations that the outbreak is a scam. Restrictions on traditional funerals, in which relatives wash and prepare the body, have angered some residents. Part of the outbreak is in Goma, a major city and humanitarian hub that rebels backed by neighboring Rwanda seized more than a year ago, which further complicates the response.
The strikes come just as the search for a treatment has begun. Earlier this month, researchers started enrolling participants in a study of two candidates. One is Gilead Sciences' remdesivir, a broad-acting antiviral approved for COVID-19 that has shown hints in lab tests of helping against Bundibugyo. The other is Mapp Biopharmaceutical's experimental MBP134, a set of engineered antibodies aimed at Ebola viruses, including Bundibugyo.
The WHO says patients will be randomly assigned to the best current standard of care alone, or with remdesivir, MBP134, both, or neither. The agency has warned that it could take months, and possibly as many as 1,000 participants, to learn whether either drug works. For now the study runs at just one treatment center in Ituri, not the one where the strike began. Officials plan to widen it to other sites once it is safe.
What to watch next: whether the government pays the strikers, whether the Bunia walkout spreads, and whether the suspected cases in two more provinces, including Kisangani, are confirmed.
Citas Notables
Striking staff agreed to resume work on the condition that the government pays them within 72 hours.— Report on the Ituri treatment center strike
It could take months and possibly as many as 1,000 study participants to tell if either drug works.— World Health Organization (paraphrased)
Quieres la nota completa?
Lee el original en The Boston Herald ↗
Health & Medicine